Background: Although the relationship between several single nucleotide polymorphisms (SNPs) of the oncogene EZH2 and cancer risk has been assessed by some case-control studies, results of subsequent studies are controversial. Sample sizes from single-center studies are also limited, thereby providing unreliable findings. Hence, we conducted a comprehensive search and meta-analysis to evaluate the associations between EZH2 SNPs and cancer risk. Materials and methods: A comprehensive literature search for studies focusing on EZH2 SNPs and cancer risk was conducted on PubMed, Web of Science, Embase, and China National Knowledge Infrastructure online databases. Genotype data were extracted and examined through a meta-analysis, and pooled odds ratios (ORs) with 95% CIs were used to assess the corresponding associations. Sensitivity analysis, publication bias assessment, and heterogeneity test were performed using STATA 12.0. Results: Twelve eligible studies were included in this meta-analysis. The association of 4 SNPs, namely, rs887569, rs2302427, rs3757441, and rs41277434, in the EZH2 locus with cancer risk was evaluated. Five studies (1,794 cases and 1,878 controls) indicated that rs887569 was related to a decreased cancer risk ( 
Introduction
Approximately 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occur in the USA in 2017. 1 Cancer is caused by uncontrolled cell division or inappropriate survival of a cell with DNA damage, which is critical for tumor initiation and progression.
Thousands of genes that are either transcriptionally upregulated or downregulated in tumor samples have been identified through microarray analysis, indicating that cancer is a disease with extreme heterogeneity. These deregulations act as the main drivers that enable tumors to invade cellular barriers, proliferate, and metastasize. 2 The dynamic regulation of histone modifications in promoters and enhancers plays a vital role in the submit your manuscript | www.dovepress.com
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ling et al control of gene expression and consequently affects disease susceptibility. EZH2 has been widely investigated because it serves as a master regulator of cancer epigenetics. 3 It is also a core component of Polycomb repressive complex 2, which mainly methylates lysine 27 of histone H3 (H3K27) to induce transcriptional gene silencing. 4 EZH2 overexpression causes epigenetic alterations in tumor suppressor genes, and such changes are required for cancer proliferation, migration, invasion, and metastasis. [5] [6] [7] Therefore, aberrant EZH2 activities may participate in increasing the risk of tumorigenesis.
The oncogenic role of EZH2 has been observed in numerous cancers, including prostate cancer, bladder cancer, breast cancer, and melanoma, whose high EZH2 expression levels are positively correlated with poor survival rate and aggressiveness. [8] [9] [10] [11] The function of EZH2 in cancer progression may also be affected by mutations. For example, the mutation of tyrosine 641 (Y641) within the C-terminal catalytic SET domain of EZH2 increases the levels of trimethylated H3K27 (H3K27me3) and thus represses the expression of Polycomb targets. 12 The loss-of-function mutations of EZH2 may occur during cancer development. The frequency of missense mutations of EZH2 in the pediatric subtype of human T-cell acute lymphoblastic leukemia (T-ALL) and early T-cell precursor (ETP) ALL is higher than that in non-ETP pediatric T-ALL. 13, 14 Similarly, single nucleotide polymorphisms (SNPs) of EZH2 may have different effects on disease susceptibility through the transcriptional regulation of genes involved in cancer initiation and progression ( Figure 1 ). Although several studies have investigated the relationship of 4 SNPs (rs887569 C.T, rs2302427 C.G, rs3757441 T.C, and rs41277434 A.C) of EZH2 and cancer risk, results are inconsistent. This relationship has yet to be systematically investigated, and definitive conclusions have yet to be presented. Hence, comprehensive reviews and meta-analyses should be performed. Here, we conducted a meta-analysis to precisely assess and provide a comprehensive conclusion about the associations between EZH2 variations and cancer risk from all eligible case-control studies published to date.
Materials and methods
Search strategy and identification of eligible studies
Two reviewers (Ling and You) searched the online databases PubMed, Google Scholar, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Wangfang Data to identify relevant articles published until September 2017. The following search terms were used either separately or in combination: "EZH2, enhancer of zeste homolog 2," "rs887569, rs2302427, rs3757441, rs41277434," "cancer, carcinoma, neoplasm," "tumor, tumour," and "SNP, polymorphism, allele, variation." Studies were limited to articles published in Chinese or English, and the references of pertinent articles were manually screened and checked. Articles that satisfied the following criteria were included: 1) studies that assessed the association between a SNP from EZH2 (rs887569, rs2302427, rs3757441, and rs41277434) and cancer risk; 2) case-control or population-based studies; and 3) studies with available genotype frequencies. Studies were excluded according to the following criteria: 1) articles that were presented as a systematic review or focusing on animals; 2) studies that involved DNA extracted from cancer tissues rather than blood samples, or studies that did not provide usable data for meta-analysis; and 3) studies that 
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association between eZh2 snPs and cancer risk reported data overlapping with those described in the included studies.
Data extraction
Two reviewers (Ling and You) independently extracted the following information from each study: first author, year of publication, cancer types, country or region, ethnicity, genotype detection method, control source of each study, number of cases and controls, polymorphism site included in each study, and results of Hardy-Weinberg equilibrium (HWE). Inconsistencies were resolved by discussion until a consensus was obtained. Newcastle-Ottawa Quality Assessment Scale was used to examine the quality of the articles included in this study. 15 
statistical analysis
The strength of the association between SNPs and cancer risk was evaluated by determining the odds ratio (OR) with 95% CI, which was calculated by Z-test, and the result of the pooled OR was considered significant when P,0.05. This association was also examined by using homozygote, heterozygote, dominant genetic, and recessive genetic models. Subgroup analyses were conducted according to cancer types and ethnic groups. Heterogeneity between articles was identified with Q-test and I 2 index. 16 When heterogeneity was observed (P,0.05 or I 2 .50%), a random-effect model (DerSimonian-Laird method) was applied; otherwise, a fixed-effect model (Mantel-Haenszel method) was utilized. 17, 18 Publication bias was evaluated by Egger's test and Begg's test, with a P-value .0.05 considered evidence Abbreviations: hB, hospital-based controls; hWe, hardy-Weinberg equilibrium; illumina, illumina goldengate platform; nOs, newcastle-Ottawa Quality assessment scale; PB, population-based controls; Pcr-rFPl, polymerase chain reaction-restriction fragment length polymorphism; sequenom, sequenom MassarraY iPleX platform; snaPshot, multiplex-Pcr snaPshot assay; TaqMan, TaqMan real-Time Pcr assays. We also conducted a stratified analysis of the data in terms of cancer types, namely, USCs and DSCs. With regard to subgroup analysis of USCs, our results did not show any association of rs887569 C.T polymorphism with cancer risk in any genotype model. However, rs2302427 C.G polymorphism was correlated with a decreased cancer risk in homozygote and recessive genetic models for DSCs. As for USCs, similar results were observed in homozygote, heterozygote, and dominant genetic models.
For rs3757441 T.C and rs41277434 A.C polymorphisms, 9 and 7 studies were included, respectively. .50%), otherwise fixed-effects models were applied. WM, WW, MM represent heterozygote, homozygote for major allele and homozygote for minor allele, respectively. Bold data is statistically significant. Abbreviations: Dsc, digestive system cancer; Usc, urogenital system cancer.
for no potential publication bias. Begg's or Egger's test was performed only for SNPs involved in 5 or more studies. Statistical tests were 2-sided, and analyses were carried out with Stata 12.0 at least twice.
Results
characteristics of the included studies
After PubMed, Google Scholar, Web of Science, Embase, CNKI, and Wangfang Data online databases were extensively screened, 216 relevant articles were identified. As shown in the flowchart in Figure 2 , 12 case-control studies involving the 4 EZH2 SNPs were finally included for further meta-analysis after ineligible articles were excluded according to our inclusion and exclusion criteria. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The characteristics of the included studies are summarized in Table 1 . Of the 12 included studies, 6 focused on digestive system cancers (DSCs; gastric cancer, hepatocellular carcinoma, colorectal cancer [CRC] , and esophageal squamous cell carcinoma), 4 examined urogenital system cancers (USCs; prostate cancer, urothelial cell carcinoma, and bladder cancer), and 2 investigated other types of cancers. The detailed information of the analyzed articles for each SNP is shown in Table S1 .
Quantitative synthesis
The associations between EZH2 SNPs and human cancer risks were evaluated (Table 2 ; Figures 3 and 4) . Overall, the EZH2 rs887569 C.T polymorphism was significantly associated with a decreased cancer risk in the dominant and recessive models (CTTT/CC: OR =0. 
sensitivity analysis and publication bias assessment
Sensitivity analyses were conducted by omitting each individual article to measure its specific effect on the pooled ORs ( Figure S3 ). The sensitivity analysis forest plot indicated that no single study significantly affected the pooled ORs for any genetic models of the 4 SNPs. A random-effect model was used when obvious heterogeneity was observed (P,0.05 or I 2 .50%); otherwise, a fixed-effect model was applied. Considering the small number of studies included in the meta-analysis, we conducted Begg's and Egger's tests to assess the publication bias for each genetic model of the 4 SNPs. No evidence of publication bias was detected in any of the homozygote, heterozygote, and dominant and recessive models of each SNP except rs3757441 and rs41277434 (Table 3) .
Discussion
EZH2 overexpression is a marker of advanced and metastatic diseases in many solid tumors, including prostate, 8 bladder, 31 gastric, 32 lung, 33 and breast cancer. 34 EZH2 has also been implicated in cancer initiation, promotion, and progression. 35 Therefore, genetic mutations may significantly influence the function of EZH2 in cancer initiation and risk. 36 Cumulative studies have suggested that recurrent heterozygous point mutations affecting tyrosine 641 (Y641) in germinal center B-cell and point mutations at alanine 687 or 677 in non-Hodgkin's lymphomas can increase H3K27me3 levels, thereby repressing the expression of Polycomb targets. [37] [38] [39] SNPs, as the most common genetic sequence variation, can affect the function of EZH2 and its downstream targets by altering EZH2 transcription and H3K27 trimethylation. For example, the rs3757441 polymorphism C/C genotype is associated with strong EZH2 and H3K27me3 immunoreactivity in primary CRC, indicating that this genotype can be a promising biomarker for EZH2-targeting agents. 27 The rs887569 TT genotype is correlated with a significantly increased overall survival and a reduced risk of mortality in patients with cholangiocarcinoma. 40 Zhou et al 22 found that the haplotypes of EZH2 genes with minor alleles of rs12670401 and rs6464926 or major alleles of rs2072407, rs734005, and rs734004 significantly increase the risk of gastric cancer, whereas the haplotypes of EZH2 genes with major alleles of rs12670401 and rs6464926 or minor alleles of rs2072407, rs734005, and rs734004 can reduce the risk of gastric cancer. These studies have demonstrated that the SNPs of EZH2 are closely related to cancer risk and prognosis. Although studies have revealed that EZH2 polymorphisms are associated with cancer risk, results are inconsistent. Therefore, we systematically reviewed the literature through a meta-analysis of the association between EZH2 gene polymorphisms and cancer risk. To the best of our knowledge, this study is the first meta-analysis to investigate the relationship between EZH2 SNPs and cancer risk.
While searching for eligible studies, we found 11 EZH2 SNPs that were reported to be associated with cancer risk: 
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association between eZh2 snPs and cancer risk population. However, the reliability of our data would have improved had we enrolled more eligible studies and a larger sample size than the obtained data. We subsequently examined the effect of EZH2 SNP rs3757441, which is a key indicator of poor prognosis in metastatic CRC, on overall cancer risk by analyzing 9 eligible studies. 27 However, in our current meta-analysis, the association between rs3757441 and cancer risk is controversial. We also performed a stratified analysis by cancer types, but no association was observed between rs3757441 and USC or DSC. These inconsistent results might be due to the heterogeneity of cancer type, ethnicity, and sample size, considering that rs3757441 plays a protective role in lung cancer in a Korean population 21 but acts as a risk factor in CRC in a Han Chinese population. 24 Furthermore, we searched for articles related to EZH2 rs41277434, and our results indicated that no significant association was found between rs41277343 and overall cancer risk or DSC risk. Sensitivity analysis revealed that the results of our study were robust. Egger's and Begg's tests indicated a publication bias in homozygote and recessive models of rs3757441 and rs41277434. Future large-scale well-designed studies should be conducted to confirm the publication bias of the genetic models of rs375441 and rs41277434.
Several limitations of our meta-analysis should be considered. First, most of the eligible studies mainly focused on East Asian populations, whereas 2 studies involved Caucasians. Studies on other ethnicities were not included in this metaanalysis. Thus, our results were incomplete. The number of eligible studies and the sample size were relatively small and 
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